0001708138-20-000014.txt : 20200227
0001708138-20-000014.hdr.sgml : 20200227
20200227161241
ACCESSION NUMBER: 0001708138-20-000014
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200225
FILED AS OF DATE: 20200227
DATE AS OF CHANGE: 20200227
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Van Plew Daniel P
CENTRAL INDEX KEY: 0001411984
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19034
FILM NUMBER: 20662169
MAIL ADDRESS:
STREET 1: REGENERON PHARMACEUTICALS, INC.
STREET 2: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0000872589
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 133444607
STATE OF INCORPORATION: NY
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
BUSINESS PHONE: 9148477000
MAIL ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
FORMER COMPANY:
FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19930328
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0306
4
2020-02-25
0
0000872589
REGENERON PHARMACEUTICALS, INC.
REGN
0001411984
Van Plew Daniel P
777 OLD SAW MILL RIVER ROAD
TARRYTOWN
NY
10591
0
1
0
0
EVP & General Mgr Industrial O
Common Stock
2020-02-25
4
M
0
32735
30.63
A
60986
D
Common Stock
2020-02-25
4
F
0
17093
447.3
D
43893
D
Common Stock
2020-02-26
4
S
0
200
451.61
D
43693
D
Common Stock
2020-02-26
4
S
0
300
452.53
D
43393
D
Common Stock
2020-02-26
4
S
0
1000
453.57
D
42393
D
Common Stock
2020-02-26
4
S
0
711
454.53
D
41682
D
Common Stock
2020-02-26
4
S
0
1300
455.5
D
40382
D
Common Stock
2020-02-26
4
S
0
1435
456.5
D
38947
D
Common Stock
2020-02-26
4
S
0
3787
457.59
D
35160
D
Common Stock
2020-02-26
4
S
0
5274
458.45
D
29886
D
Common Stock
2020-02-26
4
S
0
1425
459.33
D
28461
D
Common Stock
2020-02-26
4
S
0
210
460.3
D
28251
D
Common Stock
1537
I
By 401(k) Plan
Non-Qualified Stock Option (right to buy)
30.63
2020-02-25
4
M
0
32735
0.0
D
2020-12-14
Common Stock
32735
0
D
Represents volume-weighted average price of sales of 200 shares of Company stock on February 26, 2020 at prices ranging from $451.51 to $451.71. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price.
Represents volume-weighted average price of sales of 300 shares of Company stock on February 26, 2020 at prices ranging from $452.25 to $452.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price.
Represents volume-weighted average price of sales of 1,000 shares of Company stock on February 26, 2020 at prices ranging from $453.06 to $453.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price.
Represents volume-weighted average price of sales of 711 shares of Company stock on February 26, 2020 at prices ranging from $454.02 to $454.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price.
Represents volume-weighted average price of sales of 1,300 shares of Company stock on February 26, 2020 at prices ranging from $455.01 to $455.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price.
Represents volume-weighted average price of sales of 1,435 shares of Company stock on February 26, 2020 at prices ranging from $456.00 to $456.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price.
Represents volume-weighted average price of sales of 3,787 shares of Company stock on February 26, 2020 at prices ranging from $457.00 to $457.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price.
Represents volume-weighted average price of sales of 5,274 shares of Company stock on February 26, 2020 at prices ranging from $458.00 to $458.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price.
Represents volume-weighted average price of sales of 1,425 shares of Company stock on February 26, 2020 at prices ranging from $459.02 to $459.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price.
Represents volume-weighted average price of sales of 210 shares of Company stock on February 26, 2020 at prices ranging from $460.00 to $460.60. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price.
The option became exercisable with respect to all shares underlying the option on December 31, 2013, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2013.
/s/**Daniel P. Van Plew
2020-02-27